Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Blood|July 17, 2009
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemiaBarbara F Eichhorst, Raymonde Busch, Stephan Stilgenbauer, et al.
The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.
Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.
Blood|September 9, 2022
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J Hengeveld, Michèle Y van der Klift, P Martijn Kolijn, et al.
Communications Biology|January 16, 2021
CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemiaLennart Lenk, Michela Carlet, Fotini Vogiatzi, et al.
The Lancet. Oncology|August 18, 2018
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trialPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
Clinical Epigenetics|December 4, 2019
DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapyMaria Tsagiopoulou, Nikos Papakonstantinou, Theodoros Moysiadis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 StudyOthman Al-Sawaf, Can Zhang, Tong Lu, et al.
Blood Advances|November 23, 2021
Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric studySebastian Böttcher, Robby Engelmann, Georgiana Grigore, et al.
Blood|February 2, 2022
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemiaHenriette Huber, Simone Edenhofer, Julia von Tresckow, et al.
Pageof 8